Haugen Cange Hedda, Högmo Anders, Sandström Karl, Wennerberg Johan, Beran Martin, Söderkvist Karin, Laurell Göran, Hammarstedt-Nordenvall Lalle, Reizenstein Johan, Rydell Roland, Hafström Anna, Farnebo Lovisa
Department of Oncology, Sahlgrenska University Hospital, Goteborg, Sweden.
Regional Cancer Center West, Region Vastra Gotaland, Gothenburg, Sweden.
Cancer. 2025 Jul 1;131(13):e35955. doi: 10.1002/cncr.35955.
Radiotherapy (RT) has been the treatment of choice for T1 glottic squamous cell carcinomas with curative intent; however, transoral microsurgery (MLS) has gradually taken its place. The objective of this study was to compare the outcomes of the two treatment modalities.
The Swedish Head and Neck Cancer Register contains records for 783 patients who had T1 glottic squamous cell carcinomas and planned to undergo either RT or MLS with curative intent from 2008 until 2019. These included 652 patients with T1a tumors and 125 patients with T1b tumors, resulting in 777 eligible patients.
Surgical treatment led to an increased risk of recurrence compared with RT for patients who had both T1a and T1b tumors (p < .001). Forty-seven patients (6.0%) underwent laryngectomy after primary treatment. Patients with T1b tumors had a higher risk of undergoing laryngectomy (p = .01), but no significant difference in the frequency of laryngectomy was noted between the treatment modalities. Patients who had T1b tumors had a significantly worse 5-year overall survival rate compared with those who had T1a tumors, but treatment modality did not influence the overall survival rate.
In this population-based study of 777 patients with T1 glottic squamous cell carcinomas, no significant difference in overall survival was observed at 5 years based on treatment modality (MLS or RT). Overall survival was worse for patients with T1b carcinomas, and these patients were at an elevated risk of requiring laryngectomy. An increased risk of recurrence within 3 years was observed after surgical treatment for both T1a and T1b tumors.
放射治疗(RT)一直是治疗T1期声门鳞状细胞癌的首选治疗方法,目的是治愈;然而,经口显微手术(MLS)已逐渐取代了它的地位。本研究的目的是比较这两种治疗方式的疗效。
瑞典头颈癌登记处记录了2008年至2019年期间783例患有T1期声门鳞状细胞癌且计划接受根治性放疗或MLS的患者。其中包括652例T1a肿瘤患者和125例T1b肿瘤患者,共有777例符合条件的患者。
对于T1a和T1b肿瘤患者,与放疗相比,手术治疗导致复发风险增加(p<0.001)。47例患者(6.0%)在初次治疗后接受了喉切除术。T1b肿瘤患者接受喉切除术的风险更高(p=0.01),但两种治疗方式在喉切除术频率上没有显著差异。与T1a肿瘤患者相比,T1b肿瘤患者的5年总生存率明显更差,但治疗方式并未影响总生存率。
在这项基于人群的777例T1期声门鳞状细胞癌患者的研究中,基于治疗方式(MLS或RT),5年总生存率未观察到显著差异。T1b癌患者的总生存率更差,这些患者需要进行喉切除术的风险更高。对于T1a和T1b肿瘤,手术治疗后3年内复发风险增加。